LOS ANGELES, November 6, 2026 – CVS Health is breaking up the vast healthcare conglomerate it created over two decades. On November 4, it said it planned to break itself up into two separate publicly held corporations by the first half of 2028—divesting its insurance and pharmacy benefit management units from its retail pharmacy unit.
CVS Health, the renamed company, will own Aetna, CVS Caremark, CVS Speciality, Oak Street Health, and Signify Health. The other company, CVS Pharmacy, will own about 9,000 retail pharmacies, mail-order pharmacy, MinuteClinic and virtual care, and the Health100 technology division.
Why CVS is breaking up
This marks the end of a strategy based on vertical integration. CVS bought out Caremark in 2006, and went ahead to purchase Aetna in 2018 for $78 billion. It thus became a firm that could underwrite insurance, manage prescription drugs, and distribute them. Vertical integration is criticized for having a conflict of interest in addition to pushing up healthcare costs.
According to Julie Utterback, an analyst with Morningstar, CVS is more exposed to vertical integration among firms in this sector and management is being preemptive.
David Joyner, CEO of CVS, sees it in another way. “From a position of strength, and a focus on the long term, we plan to create two focused companies to improve consumer engagement, affordability, and care coordination,” he said in the announcement.
Who runs what
Joyner will head the healthcare solutions company that will keep the CVS Health name. Prem Shah, who is the current group president, will become CEO of CVS Pharmacy.
The carve-out is meant to be tax-free for CVS and its shareholders, who will hold stakes in both companies following the transaction. CVS says each of the two companies will have an excellent investment-grade profile, robust free cash flow, and an attractive dividend payout.
Investors weren’t impressed
The market reaction was harsh. CVS shares closed down 12.5% at $79.96 on November 4, erasing nearly $15 billion in market value.
Why? The breakup came despite solid third-quarter results: adjusted earnings of $2.09 per share beat the $1.65 analysts expected, and CVS raised its full-year 2026 adjusted profit forecast to at least $8.20 per share. But investors appeared to want more financial detail on how the two companies would perform separately.
UBS analyst Kevin Caliendo said the split was perceived as “a defensive move against regulation rather than an offensive move.” Barclays analyst Andrew Mok pointed to the lack of financial specifics, noting that CVS once promised at least $500 million in synergies when it acquired Caremark two decades ago.
What it means for customers
For now, nothing changes at the pharmacy counter. CVS says customers, patients, and clients will continue receiving medicines, benefits, and services without interruption while the separation proceeds.
The longer-term question is whether two focused companies can actually deliver what the combined giant promised: lower costs, simpler care, and better access. CVS says its pharmacy business will pursue partnerships with insurers, pharmacy benefit managers, and manufacturers; the healthcare company will focus on benefits, care delivery, and cost management.
That’s the bet. After years of buying businesses to build an integrated healthcare machine, CVS is wagering that smaller, sharper companies can serve patients—and shareholders—better than one enormous one.
